Subcutaneous Panniculitis-Like T-Cell Lymphoma
NCI Definition: A cytotoxic primary cutaneous T-cell lymphoma. Recent studies suggest there are at least two groups of subcutaneous panniculitis-like T-cell lymphomas, each with distinct histologic features, immunophenotypic profile, and prognosis. One group has an alpha/beta, CD8 positive phenotype, involves only subcutaneous tissues, and usually has an indolent clinical course. The second group has a gamma/delta phenotype, is CD8 negative, often co-expresses CD56, is not confined to the subcutaneous tissues, and usually has a poor prognosis. In the recent WHO-EORTC classification, the term subcutaneous panniculitis-like T-cell lymphoma is reserved for cases with an alpha/beta, CD8 positive phenotype. Cases with a gamma/delta phenotype are included in the group of cutaneous gamma/delta T-cell lymphomas. 
There are 6 clinical trials for subcutaneous panniculitis-like T-cell lymphoma, of which 6 are open and 0 are completed or closed. Of the trials that contain subcutaneous panniculitis-like T-cell lymphoma as an inclusion criterion, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 1 is no phase specified (1 open).
Azacitidine, doxorubicin, and romidepsin are the most common interventions in subcutaneous panniculitis-like T-cell lymphoma clinical trials.
Significant Genes in Subcutaneous Panniculitis-Like T-Cell Lymphoma
ALK is an inclusion eligibility criterion in 1 clinical trial for subcutaneous panniculitis-like T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and subcutaneous panniculitis-like T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.